0.781
-0.08 (-9.54%)
| Previous Close | 0.863 |
| Open | 0.840 |
| Volume | 374,498 |
| Avg. Volume (3M) | 487,971 |
| Market Cap | 37,944,392 |
| Price / Sales | 10.21 |
| Price / Book | 1.77 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Operating Margin (TTM) | -6,511.20% |
| Diluted EPS (TTM) | -1.64 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 64.59% |
| Current Ratio (MRQ) | 8.10 |
| Operating Cash Flow (TTM) | -59.84 M |
| Levered Free Cash Flow (TTM) | -36.80 M |
| Return on Assets (TTM) | -32.66% |
| Return on Equity (TTM) | -82.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Werewolf Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -5.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -2.5 |
| Average | -0.50 |
|
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.07% |
| % Held by Institutions | 62.75% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| EVNIN LUKE | - | 0.626 | -146,512 | -91,435 |
| RA CAPITAL MANAGEMENT, L.P. | - | 0.647 | -188,641 | -121,758 |
| Aggregate Net Quantity | -335,153 | |||
| Aggregate Net Value ($) | -213,194 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 0.634 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| EVNIN LUKE | Director | 13 May 2026 | Automatic sell (-) | 44,679 | 0.584 | 26,093 |
| RA CAPITAL MANAGEMENT, L.P. | 12 May 2026 | Sell (-) | 101,151 | 0.632 | 63,927 | |
| EVNIN LUKE | Director | 12 May 2026 | Automatic sell (-) | 67,885 | 0.632 | 42,903 |
| RA CAPITAL MANAGEMENT, L.P. | 11 May 2026 | Sell (-) | 87,490 | 0.661 | 57,831 | |
| EVNIN LUKE | Director | 11 May 2026 | Automatic sell (-) | 33,948 | 0.661 | 22,440 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |